Amir Inamdar is the Chief Medical Officer at Cybin Inc., bringing more than 20 years of clinical medicine and drug-development experience. Prior to joining Cybin, Amir held senior roles in industry including Senior Medical Director for R&D Neurosciences at AstraZeneca, Medical Director at Takeda Development Centre Europe Ltd., and Director of Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline. He's led global teams in advancing novel therapies across indications such as treatment-resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance-use disorders — and steered compounds from preclinical development through first-in-human and proof-of-concept studies